Ozempic and Gastroparesis: Understanding the Evidence and Your Options

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Legal Guidance

If you or someone you know has experienced persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be wondering if the medication could be linked to gastroparesis. Medical research has increasingly examined this potential connection, building on a long tradition of post-market surveillance that evaluates both benefits and risks of widely used treatments. This page reviews the current evidence and what it means for patients.

The Medical Link Between Ozempic and Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacological action includes slowing gastric emptying, which is a known mechanism that can contribute to gastrointestinal adverse effects. Gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, presents clinically with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath tests to confirm delayed emptying. The overlap between Ozempic's intended effect on gastric motility and the pathophysiology of gastroparesis raises concerns about a causal link between the drug and the development or exacerbation of this condition. Clinical trial data from the Ozempic prescribing information indicate that gastrointestinal adverse reactions occur significantly more frequently in patients receiving Ozempic compared to placebo. In pooled placebo-controlled trials, gastrointestinal adverse reactions were reported in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of nausea, vomiting, and diarrhea occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher in Ozempic-treated patients (3.1% for 0.5 mg and 3.8% for 1 mg) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in at least 5% of Ozempic-treated patients include nausea (20.3% on 1 mg vs. 6.1% placebo), vomiting (9.2% vs. 2.3%), diarrhea (8.8% vs. 1.9%), abdominal pain (5.7% vs. 4.6%), and constipation (3.1% vs. 1.5%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms are consistent with the clinical presentation of gastroparesis.

Postmarketing Evidence and Risk Context

Postmarketing reports further highlight a mechanistic pathway linking Ozempic to gastroparesis. There have been rare reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation, who had residual gastric contents despite reported adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This finding underscores the drug's effect on delayed gastric emptying, which is a core feature of gastroparesis. The prescribing information notes that available data are insufficient to recommend modifications to preoperative fasting or temporary discontinuation to mitigate this risk, but it instructs patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This warning indicates that the drug's impact on gastric motility is recognized as clinically significant. From a risk perspective, the adequacy of warnings regarding Ozempic and gastroparesis is a critical consideration. The prescribing information does not explicitly list gastroparesis as a contraindication or warning, but it does detail gastrointestinal adverse reactions and the risk of retained gastric contents during anesthesia. Patients who develop persistent symptoms of gastroparesis—such as chronic nausea, vomiting, abdominal pain, and early satiety—after starting Ozempic may not have been adequately informed about this potential adverse effect. The timeline between exposure and documented harm is variable; symptoms often emerge during dose escalation, as noted in clinical trials, but may also develop after prolonged use. For affected patients, documenting the onset of symptoms relative to Ozempic initiation is crucial for establishing a temporal relationship.

Statute of Limitations for Ozempic Claims in New York

Attorney-related considerations for patients in New York involve the statute of limitations for filing a product liability claim. In New York, the statute of limitations for personal injury claims is generally three years from the date of injury, while for wrongful death, it is two years from the date of death. However, the discovery rule may apply, meaning the clock starts when the injury is discovered or reasonably should have been discovered. For gastroparesis linked to Ozempic, this could be when a patient receives a formal diagnosis or when symptoms become severe enough to seek medical attention. Patients should consult with an attorney promptly to assess their specific timeline, as delays could bar recovery. Evidence of harm, such as medical records documenting gastroparesis diagnosis and Ozempic prescription, along with the prescribing information's adverse reaction data, can support a claim that the drug's warnings were insufficient. In summary, the clinical and pharmacological evidence supports a plausible link between Ozempic and gastroparesis through delayed gastric emptying. The high incidence of gastrointestinal adverse reactions in clinical trials and postmarketing reports of retained gastric contents during anesthesia underscore this risk. Patients in New York who have developed gastroparesis after using Ozempic should be aware of the statute of limitations and seek legal counsel to evaluate their options. The adequacy of warnings remains a central issue, as the prescribing information does not directly address gastroparesis despite the drug's known effects on gastric motility.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in New York?

In New York, the statute of limitations for personal injury claims is generally three years from the date of injury, and for wrongful death, two years from the date of death. However, the discovery rule may apply, meaning the clock starts when the injury is discovered or reasonably should have been discovered. For gastroparesis linked to Ozempic, this could be when a patient receives a formal diagnosis or when symptoms become severe enough to seek medical attention. It is crucial to consult with an attorney promptly to assess your specific timeline.

How does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism of action. This can lead to gastrointestinal adverse effects such as nausea, vomiting, and delayed gastric emptying, which are consistent with gastroparesis. Clinical trials show a significantly higher incidence of gastrointestinal adverse reactions in Ozempic-treated patients compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Postmarketing reports also highlight the risk of retained gastric contents during anesthesia (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.